John Fraser is a clinician scientist, innovator and disruptor. His scientific endeavours highlighted to him the potential of medical technologies in the heart and lung arena when developed symbiotically with world class clinicians, researchers, developers - with the patient at the centre of these innovations.

In his roles as the founder of the CCRG ( https://ccrg.org.au ) , Australia’s largest acute care multidisciplinary research group in Australia, Founder of medical device company De Motu Cordis Pty Ltd (. https://demotucordis.co/) , and as an intensive care medicine specialist, Prof Fraser has seen time and again how the best and brightest innovators in the areas of cardiovascular, respiratory and chronic disease continue to face a critical funding gap to transport their early to mid stage innovations through to manufacture and commercialisation. It is through this gap that opportunities fall - and potential game-changing technologies can be lost.

As a result, Prof Fraser has co-founded the Quantum Medical Innovation Fund, focussing on medical innovations that make a quantum difference to both to patient outcomes and investor returns. Quantum’s unique advantage is its productive global network of medical and innovation leaders, thereby de-risking the investment decision making around early and mid-stage med-tech assets, and subsequently applying a strategy of active management to drive positive target outcomes. It is his network that facilitated the birth of the COVID Consortium ( https://www.covid-critical.com) - a global Critical Care Community born across 55 countries and approx 400 hospitals to share data , create real time dashboards with IBM and work towards the use of AI in management of COVID 19.

Prof Fraser continues to push at the boundaries of medicine, science and technology, all in the pursuit of ensuring that critically ill patients across the world have every opportunity to thrive - not just survive.